title: [Clinical significance of matrix metalloproteinase-9 and tissue factors secreted by cultured monocyte-derived macrophage of patients with coronary heart disease in vitro and the intervenient effect of puerarin on them].
abstract: OBJECTIVE
  To investigate the clinical significance of matrix metalloproteinase-9 (MMP-9) and tissue factor (TF) secreted by cultured monocyte-derived macrophages (HMDM) from patients with coronary heart disease (CHD) in vitro, and to evaluate the intervenient effect of puerarin (Pur) on them.
  
  
  METHODS
  A total of 40 patients were enrolled, including 12 patients with acute myocardial infarction (AMI), 16 patients with unstable angina pectoris (UAP), 12 patients with stable angina pectoris (SAP). Besides, 8 healthy subjects with normal coronary arteriograph were set as controls. Monocytes acquired from their peripheral blood were incubated for 48 h and induced to differentiate into macrophages by phorbolester 12-myristate 13-acetate (PMA), the contents of MMP-9 and TF in supernatant were assayed, and the relationship of them with patients' age, risk factors of CHD and coronary artery lesion scores were analyzed. HMDMs randomly from selected 12 patients with acute coronary syndrome (ACS) were arranged for observing the intervenient effects of different concentrations of Pur on the levels and activity of MMP-9 and TF.
  
  
  RESULTS
  The levels of MMP-9 and TF in UAP and AMI patients were significantly higher than those in SAP patients and healthy subjects (P < 0.01), but no statistical correlation was found between levels of MMP-9 and TF with different CHD risk factors, as well as patients' age and coronary artery lesion scores. The levels and activity of MMP-9 and TF in the 12 ACS patients were significantly decreased in a dose-dependent manner after Pur intervention when compared with the controt group.
  
  
  CONCLUSIONS
  The levels of MMP-9 and TF secreted in vitro by HMDM from CHD patients could be taken as indexes for evaluating patient's condition of ACS. Pur can inhibit the expression and the activity of MMP-9 and TF secreted by HMDM, stabilize the plaque and improve the vulnerability of blood to certain extent.
authors: Department Of Cardiology, Affiliated Hospital of Xuzhou. dongyeli@yahoo.com
authors: Dong-ye
authors: DY
authors: Li
authors: Zi-long
authors: ZL
authors: Wang
authors: Yonrg
authors: Y
authors: Xia
mesh_terms: D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009000:Monocytes / Q000473:pathology; D013925:Thromboplastin / Q000378:metabolism*; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D007529:Isoflavones; D014665:Vasodilator Agents; D013925:Thromboplastin; D020780:Matrix Metalloproteinase 9; C033607:puerarin